December 23, 2011—An organization of over 800 non-profit and public hospitals that participate in the 340B program has written to drug manufacturer Sanofi-Aventis to express concern over the discontinuation of its institutional patient assistance program as well as the termination of its free drug program for the anti-coagulant Lovenox. In the letter, Safety Net Hospitals … [Read more...]
Prices Aren’t Causing Drug Shortages, Experts Tell Senate Panel
Solution lies in strengthening FDA's authority, witnesses agree.December 16, 2011—Witnesses testifying at a Senate committee hearing yesterday—including the head of the trade association for generic pharmaceutical manufacturers—overwhelmingly concurred that government drug pricing programs such as 340B are not the reason why so many generic injectable drugs are in short supply. The Senate Health, Education, Labor and Pensions (HELP) … [Read more...]
Congress Level-Funds OPA and Declines to Approve User Fee
Former OPA director thinks audits and other program integrity initiatives will remain high priorities.December 16, 2011—Congressional negotiators last night approved a $1 trillion fiscal year 2012 spending agreement for much of the federal government that level-funds the Office of Pharmacy Affairs (OPA) at its current $4.48 million. The measure does not include a proposed user fee that was expected to raise an additional $5 million to finance 340B program integrity … [Read more...]
OPA-CMS Webinar Focuses on Preventing 340B Duplicate Discounts
Pedley reminds providers of their responsibility to keep OPA database up to date.December 15, 2011—With 340B covered entity audits just over the horizon, providers that use 340B drugs for Medicaid patients should double-check the accuracy of their information in the Office of Pharmacy Affairs (OPA) database lest they find themselves on the hook for a duplicate discount violation, the office's director recommended during a recent webinar. Also, auditors … [Read more...]
Sanofi Discontinues Its Institutional Patient Assistance Program
Providers says IPAP's demise will strain their budgets and could compromise patient care.December 9, 2011—Safety-net hospitals and free and charitable clinics say they are scrambling to replace formerly free bulk supplies of Sanofi U.S. medications, including the widely used anticoagulant Lovenox (enoxaparin), following the drug manufacturer's mid-November notice that it is discontinuing its entire institutional patient assistance program (IPAP) at the end of … [Read more...]
Senate Committee Seeks Answers on Drug Shortages
340B's role raised again, just as it was during House session a week earlier.December 8, 2011—A second congressional committee in as many weeks has heard expert testimony on what is causing critical shortages of generic injectable drugs, including whether 340B drug discounts are part of the problem and, if so, to what degree. The Dec. 7 Senate Finance Committee hearing came just eight days after the one held by the House Oversight and Government … [Read more...]
Experts Link Medicare Reimbursement to Drug Shortages
Witnesses at House hearing disagree over whether 340B contributes to the problem.December 2, 2011—Witnessesses testifying before a U.S. House subcommittee largely agreed that Medicare pharmacy reimbursement is one of the core reasons behind critical shortages of generic injectable drugs, but they differed over whether 340B discounts are a factor. … [Read more...]